Antimicrobial treatment and outcomes of critically ill patients with OXA-48like carbapenemase-producing Enterobacteriaceae infections

Diagnostic Microbiology and Infectious Disease

Volumn 81, Issue 2, 2015, Pages 138-140

  Lowman, Warren ^a,b   Schleicher, Gunter ^b  

^a Microbiology Department Pathlink Laboratories   (South Africa)

^b University of the Witwatersrand   (South Africa)

Author keywords

Carbapenemase producing Enterobacteriaceae (CPE); Intensive care unit; Mortality; OXA 48; Treatment

Indexed keywords

AMIKACIN; CARBAPENEM; CARBAPENEMASE; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; ERTAPENEM; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; CARBAPENEM DERIVATIVE;

ADULT; AGED; ANTIMICROBIAL THERAPY; APACHE; ARTICLE; BACTEREMIA; BACTERIAL GENE; BACTERIUM ISOLATE; BLAGES GENE; BLAKPC GENE; BLANDM GENE; BLAOXA GENE; BLAVIM GENE; CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE; CLINICAL ARTICLE; COMORBIDITY; CRITICALLY ILL PATIENT; DISEASE SEVERITY; ENTEROBACTERIACEAE INFECTION; FEMALE; GENE IDENTIFICATION; HUMAN; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; LENGTH OF STAY; LIVER ABSCESS; MALE; MORTALITY; NONHUMAN; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; CRITICAL ILLNESS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; ENZYMOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; SECRETION (PROCESS); SURVIVAL; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEMS; CRITICAL ILLNESS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84922412074     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2014.09.023     Document Type: Article

References (12)

1. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing; twenty third informational supplement, M100-S23. CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania, 19087-1898 USA 2013.
2. Horan T.C., Andrus M., Dudeck M.A. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008, 36:309-332.
3. Knaus W.A., Wagner D.P., Draper E.A., Zimmerman J.E., Bergner M., Bastos P.G., et al. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991, 100:1619-1636.
4. Lavigne J.P., Cuzon G., Combescure C., Bourg G., Sotto A., Nordmann P. Virulence of Klebsiella pneumoniae isolates harboring bla KPC-2 carbapenemase gene in a Caenorhabditis elegans model. PLoS One 2013, 8:e67847.
5. Lowman W., Marais M., Ahmed K., Marcus L. Routine active surveillance for carbapenemase-producing Enterobacteriaceae from rectal swabs: diagnostic implications of multiplex polymerase chain reaction. J Hosp Infect 2014, 88:66-71.
6. McLaughlin M.M., Advincula M.R., Malczynski M., Barajas G., Qi C., Scheetz M.H. Quantifying the clinical virulence of Klebsiella pneumoniae producing carbapenemase Klebsiella pneumoniae with a Galleria mellonella model and a pilot study to translate to patient outcomes. BMC Infect Dis 2014, 14:31.
7. Munoz-Price L.S., Poirel L., Bonomo R.A., Schwaber M.J., Daikos G.L., Cormican M., et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 2013, 13:785-796.
8. Navarro-San Francisco C., Mora-Rillo M., Romero-Gomez M.P., Moreno-Ramos F., Rico-Nieto A., Ruiz-Carrascoso G., et al. Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae: a major clinical challenge. Clin Microbiol Infect 2013, 19:E72-E79.
9. Poirel L., Potron A., Nordmann P. OXA-48-like carbapenemases: the phantom menace. J Antimicrob Chemother 2012, 67:1597-1606.
10. Roberts J.A., Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009, 37:840-851. [quiz 859].
11. Shorr A.F. Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit. Crit Care Med 2009, 37:1463-1469.
12. Tzouvelekis L.S., Markogiannakis A., Psichogiou M., Tassios P.T., Daikos G.L. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 2012, 25:682-707.